DNER and neoplasm: BET bromodomain inhibitor molibresib combined with anti-PD-L1 shows enhanced anti-tumor effects by decreasing Monocytic-MDSC and increasing tumor-infiltrating lymphocytes (TILs) in fibrotic HCC mouse models (112).